Takeda’s dengue vaccine candidate demonstrates protection in children aged four to 16 years,… EP News Bureau Nov 8, 2019 Takeda’s dengue vaccine candidate was generally well-tolerated, and no important safety risks have been observed to date
Novartis’ two major trials shows significant efficacy of Cosentyx in ankylosing spondylitis… Usha Sharma Dec 24, 2015 The study enrolled anti-TNF naïve patients and patients who had previously failed anti-TNF therapy, with clinical benefits…
Sanofi Pasteur’s vaccine candidate protects pre-adolescents to adults against dengue Sanjiv Das Jul 28, 2015 Based on the clinical profile in nine years of age and older, the dengue vaccine candidate has the potential to significantly…
